BeiGene teams up with Pfizer spin-out again

Chinese cancer specialist BeiGene (HKEX: 06160) has entered into a second collaboration with SpringWorks Therapeutics, a spin-out from US pharma giant Pfizer (NYSE: PFE).

While the first collaboration was based around combining BeiGene's RAF dimer inhibitor, lifirafenib, and SpringWorks' MEK inhibitor, PD-0325901, in advanced solid tumors, this partnership will see them create an entirely new entity.

They will jointly own the new company, called MapKure, and its purpose will be to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.